Clinical Trial Results

« Previous 1234 Next »
Viewing Page 1 of 4 | Showing Results 1 - 10 of 37

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

This trial collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies....

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of TAK-676 administered as an SA or in combination with pembrolizumab in...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

RWF: A First-in-Human Phase 1 Study of NL-201 in Patients With Relapsed or Refractory Cancer

The primary purpose of this study is to understand the safety of NL-201 when given intravenously as monotherapy in patients with advanced cancer to...

Brendan Curti, M.D.
  • Providence Cancer Institute Franz Clinic

Molecular Analysis for Therapy Choice (MATCH)

This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)

This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma, refractory or resistant to...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1b/2 Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of TAK-981 in combination with pembrolizumab in participants with select...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and...

Charles Drescher, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, and efficacy in participants with advanced/metastatic or recurrent malignancies...

Rom Leidner, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

RWF: A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors

This study is a multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AGEN1777 as a...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic
« Previous 1234 Next »
Viewing Page 1 of 4 | Showing Results 1 - 10 of 37